title: [The homocysteinemia vascular risk factor. Methodologies and application to a clinical case].
abstract: Early onset vascular disease unexplained until today by usual risk factors (hyperlipidemia, hypertension, tobacco, stress), can now find an explanation in sulfur amino acid metabolism defect. By transsulfuration, alimentary methionine leads to homocysteine, which is itself turn into cysteine, or remethylated into methionine. Several abnormalities of these different pathways lead to plasma accumulation of homocysteine, which will be responsible of arterial or venous occlusive lesions, concerning peripheral or deep vessels. Homocysteine stays in plasma upon several forms: 75% being linked by disulfide bounds to proteins, 22% as disulfide, homocystine (homocysteine-homocysteine) or mixed-disulfide (homocysteine-cysteine), and less than 3% as free reduced homocysteine. Plasma reduction allows total homocysteine evaluation with amino acid autoanalyzer. The basal plasma homocysteine level is less than 14 microMl. However, levels near this basal value can be found in patients with latent abnormality, which needs to be revealed by a methionine loading test. This study concerns two methodologies and their application to the exploration of a patient with unidentified neurologic disorders. The first one describes a new galenic oral form of methionine. Other authors use the methionine load of 100 mg/kg dissolving it in a fruit juice glass. In order to obtain a complete dissolution of this weakly soluble substance and to ensure its total absorbtion by the patient, we prepare a granular form aimed to give in water a perfect flavoured suspension. The second methodology concerns methionine loading test and amino acid analysis. After 10 hours fasting, a 100 mg/kg peroral methionine load is realized performing 5 EDTA blood samples before and 4, 8, 12 and 24 hours after loading.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratoire de Chimie Biologique, INSERM U278 Faculté de Pharmacie, Marseille.
authors.forename: D
authors.initials: D
authors.lastname: Garçon
authors.forename: A
authors.initials: A
authors.lastname: Barlatier
authors.forename: P
authors.initials: P
authors.lastname: Charpiot
authors.forename: R
authors.initials: R
authors.lastname: Calaf
authors.forename: J
authors.initials: J
authors.lastname: Joachim
authors.forename: S
authors.initials: S
authors.lastname: Perrin
authors.forename: M
authors.initials: M
authors.lastname: Habib
authors.forename: P
authors.initials: P
authors.lastname: Ambrosi
authors.forename: A
authors.initials: A
authors.lastname: Friggi
authors.forename: H
authors.initials: H
authors.lastname: Bodard
mesh_terms: D000596:Amino Acids / Q000097:blood; D001157:Arterial Occlusive Diseases / Q000097:blood; D002845:Chromatography; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D008715:Methionine; D008875:Middle Aged; D015394:Molecular Structure; D012307:Risk Factors; D014652:Vascular Diseases / Q000097:blood*
chemical_list: D000596:Amino Acids; D006710:Homocysteine; D008715:Methionine
vernacular_title: L'homocystéinémie facteur de risque vasculaire. Méthode de mise en évidence, application à un cas clinique.